'Mod­er­na will be a rare dis­ease com­pa­ny,' CEO says, as mR­NA com­pa­ny plots ex­pan­sion in ge­net­ic dis­eases and eyes n-of-1 treat­ments

Just a few years ago, Mod­er­na faced a cho­rus of doubts over whether its ex­per­i­men­tal mR­NA tech­nol­o­gy would ever work well enough to be­come a med­i­cine. Af­ter the $36 bil­lion suc­cess of its Covid-19 vac­cines, the ques­tion now be­comes: What’s next?

The biotech’s an­swer over the past year has been “more of every­thing,” in­clud­ing an ex­pan­sive in­fec­tious dis­ease vac­cine pipeline and de­vel­op­ing per­son­al­ized can­cer vac­cines with Mer­ck. And now, ear­ly signs of suc­cess us­ing the mes­sen­ger mol­e­cule to make ther­a­peu­tic pro­teins in the liv­er have Mod­er­na ec­sta­t­ic about yet an­oth­er ap­pli­ca­tion for mR­NA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA